Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Castaigné · SciRah

Researcher profile · Semantic Scholar

S. Castaigné

Share profile

S. Castaigné — researcher profile on SciRah

h-index: 64
Works: 302
Citations: 17K

Most-cited papers

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
B. Coiffier, C. Thieblemont, E. Van Den Neste, G. Lepeu +10 more
2010Blood1,422 citations Open access
Semantic Scholar
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
S. Castaigné, C. Pautas, C. Terré, E. Raffoux +18 more
2012The Lancet920 citations
Semantic Scholar
The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy in Acute Myeloid Leukaemia : An IndividualPatient Data Meta-analysis of Randomised Trials in Adults
R. Hills, S. Castaigné, F. Appelbaum, J. Delaunay +11 more
2014The Lancet Oncology628 citations Open access
Semantic Scholar
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
F. Peyrade, F. Jardin, C. Thieblemont, A. Thyss +17 more
2011The Lancet Oncology492 citations
Semantic Scholar
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
S. Prost, Francis Relouzat, M. Spentchian, Yasmine Ouzegdouh +11 more
2013Nature256 citations Open access
Semantic Scholar
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
C. Pautas, F. Merabet, X. Thomas, E. Raffoux +16 more
2010Journal of Clinical Oncology223 citations Open access
Semantic Scholar
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
N. Boissel, O. Nibourel, Aline Renneville, C. Gardin +14 more
2010Journal of Clinical Oncology219 citations
Semantic Scholar
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
N. Mounier, T. El Gnaoui, H. Tilly, D. Canioni +12 more
2013Haematologica171 citations Open access
Semantic Scholar
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
J. Lambert, C. Pautas, C. Terré, E. Raffoux +13 more
2018Haematologica157 citations Open access
Semantic Scholar
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association
Aline Renneville, N. Boissel, O. Nibourel, C. Berthon +16 more
2011Leukemia127 citations
Semantic Scholar
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
J. Micol, Nicolas Duployez, N. Boissel, A. Petit +14 more
2014Blood120 citations Open access
Semantic Scholar
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
H. Debarri, D. Lebon, C. Roumier, M. Cheok +17 more
2015OncoTarget114 citations Open access
Semantic Scholar
Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion
Zena Khaznadar, N. Boissel, S. Agaugué, Guylaine Henry +13 more
2015Journal of Immunology88 citations
Semantic Scholar
MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
J. Lambert, J. Lambert, O. Nibourel, C. Pautas +9 more
2014OncoTarget78 citations Open access
Semantic Scholar
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial.
É. Fournier, Nicolas Duployez, B. Ducourneau, E. Raffoux +17 more
2019Blood76 citations
Semantic Scholar
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
C. Gardin, S. Chevret, C. Pautas, P. Turlure +15 more
2013Journal of Clinical Oncology76 citations Open access
Semantic Scholar
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
M. Buyse, P. Squifflet, B. Lange, T. Alonzo +10 more
2011Blood72 citations Open access
Semantic Scholar
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
Olivia Roth, O. Spreux‐Varoquaux, S. Bouchet, P. Rousselot +7 more
2010Clinica chimica acta; international journal of clinical chemistry71 citations
Semantic Scholar
The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
Guillaume Olombel, Estelle Guérin, J. Guy, J. Perrot +17 more
2016Blood67 citations Open access
Semantic Scholar
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index
C. Sarkozy, C. Terré, F. Jardin, I. Radford +14 more
2014Genes, Chromosomes and Cancer67 citations
Semantic Scholar
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
N. Dang, M. Ogura, S. Castaigné, L. Fayad +13 more
2017British Journal of Haematology64 citations Open access
Semantic Scholar
Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
J. Bibault, M. Figeac, N. Hélevaut, C. Rodriguez +9 more
2015OncoTarget63 citations Open access
Semantic Scholar
Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial
G. Cannas, C. Pautas, E. Raffoux, B. Quesnel +11 more
2012Leukemia and Lymphoma58 citations
Semantic Scholar
Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
E. Abdelhamid, C. Preudhomme, N. Hélevaut, O. Nibourel +7 more
2012Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis57 citations
Semantic Scholar
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
X. Thomas, M. Elhamri, E. Raffoux, Aline Renneville +16 more
2011Blood55 citations Open access
Semantic Scholar
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
Aline Renneville, R. B. Abdelali, S. Chevret, O. Nibourel +13 more
2014OncoTarget53 citations Open access
Semantic Scholar
Outcome of older patients with acute myeloid leukemia in first relapse
C. Sarkozy, C. Gardin, N. Gachard, Fathia Merabet +13 more
2013American journal of hematology/oncology51 citations
Semantic Scholar
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
T. Braun, S. de Botton, A. Taksin, Sophie Park +18 more
2011Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis45 citations
Semantic Scholar
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.
E. Paubelle, Florence Zylbersztejn, T. Maciel, C. Carvalho +22 more
2020Cell Reports43 citations Open access
Semantic Scholar
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group
Yann Ferret, N. Boissel, N. Hélevaut, J. Madic +11 more
2018Haematologica40 citations Open access
Semantic Scholar
Copy-number analysis identified new prognostic marker in acute myeloid leukemia
O. Nibourel, S. Guihard, C. Roumier, N. Pottier +17 more
2017Leukemia39 citations
Semantic Scholar
Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial
N. Vey, P. Dumas, C. Récher, L. Gastaud +31 more
201736 citations
Semantic Scholar
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission
M. Buyse, S. Michiels, P. Squifflet, K. Lucchesi +4 more
2011Haematologica36 citations Open access
Semantic Scholar
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
B. Deau, F. Nicolini, J. Guilhot, F. Huguet +16 more
2011Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis35 citations
Semantic Scholar
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
X. Thomas, S. de Botton, S. Chevret, D. Caillot +17 more
2017Journal of Clinical Oncology34 citations
Semantic Scholar
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70‐year old: A phase 1/2 study of the acute leukemia French association
H. Farhat, O. Reman, E. Raffoux, C. Berthon +8 more
2012American journal of hematology/oncology33 citations Open access
Semantic Scholar
The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.
A. Renneville, N. Boissel, N. Gachard, Dina Naguib +11 more
2009Blood33 citations Open access
Semantic Scholar
Performance of Serum Biomarkers for the Early Detection of Invasive Aspergillosis in Febrile, Neutropenic Patients: A Multi-State Model
M. Schwarzinger, L. Sagaon-Teyssier, O. Cabaret, S. Bretagne +48 more
2013PLoS ONE32 citations Open access
Semantic Scholar
Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)
S. Castaigné, C. Pautas, C. Terré, E. Raffoux +27 more
201132 citations
Semantic Scholar
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
L. Fenwarth, É. Fournier, M. Cheok, T. Boyer +7 more
2020International Journal of Molecular Sciences27 citations Open access
Semantic Scholar
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
J. Lambert, J. Lambert, X. Thomas, A. Marceau-Renaut +16 more
2021Blood Advances26 citations Open access
Semantic Scholar
Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria
R. Itzykson, C. Gardin, C. Pautas, X. Thomas +7 more
2011Haematologica26 citations Open access
Semantic Scholar
Final Analysis of the ALFA 0701 Study
S. Castaigné, C. Pautas, C. Terré, Aline Renneville +10 more
201425 citations
Semantic Scholar
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse
S. Pilorge, S. Rigaudeau, Florence Rabian, C. Sarkozy +11 more
2014American journal of hematology/oncology23 citations Open access
Semantic Scholar
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
D. Ghez, J. Micol, F. Pasquier, N. Auger +10 more
2013European Journal of Cancer19 citations
Semantic Scholar
Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations
A. Marceau-Renaut, S. Guihard, S. Castaigné, H. Dombret +2 more
2015American journal of hematology/oncology18 citations Open access
Semantic Scholar
Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia
P. Peterlin, Aline Renneville, R. Ben Abdelali, O. Nibourel +12 more
2014Haematologica15 citations Open access
Semantic Scholar
Frequent ASXL 2 mutations in acute myeloid leukemia patients with t ( 8 ; 21 ) / RUNX 1-RUNX 1 T 1 chromosomal translocations
J. Micol, Nicolas Duployez, N. Boissel, A. Petit +14 more
201415 citations
Semantic Scholar
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
C. Pautas, E. Raffoux, J. Lambert, O. Legrand +10 more
2021Bone Marrow Transplantation14 citations Open access
Semantic Scholar
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).
N. Dang, M. Ogura, S. Castaigné, L. Fayad +13 more
201414 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Dombret×34
Invite
H. Dombret — researcher profile on SciRah
C. Preudhomme×31
Invite
C. Preudhomme — researcher profile on SciRah
C. Pautas×24
Invite
C. Pautas — researcher profile on SciRah
C. Terré×24
Invite
C. Terré — researcher profile on SciRah

×19

Invite

E. Raffoux — researcher profile on SciRah

Invite

X. Thomas — researcher profile on SciRah

P. Rousselot×17

Invite

P. Rousselot — researcher profile on SciRah

Invite

C. Gardin — researcher profile on SciRah

Invite

N. Boissel — researcher profile on SciRah

Aline Renneville×17

Invite

Aline Renneville — researcher profile on SciRah

Invite

S. Chevret — researcher profile on SciRah

O. Nibourel×13

Invite

O. Nibourel — researcher profile on SciRah